Drug details

Rystiggo (rozanolixizumab-noli injection)

type of Fc Receptor Antagonists

Rystiggo (rozanolixizumab-noli) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti- muscle-specific tyrosine kinase (MuSK) antibody positive.

The drug is often used to treat Myasthenia gravis .

This drug may have the following side effects:

• nausea,
• diarrhea,
• fever,
• headache,
• abdominal pain, and
• hypersensitivity reactions,
• joint pain.
• administration site reactions,

The following drugs are related to Rystiggo, either as a replacement or used together:

• Astagraf XL (tacrolimus extended-release capsules)
• Azasan (azathioprine)
• Imuran (azathioprine)
• CellCept (mycophenolate mofetil)
• Sandimmune (cyclosporine)
• Gengraf Capsules (cyclosporine capsules)
• Gengraf Oral Solution (cyclosporine oral solution)
• Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc injection)
• Vyvgart (efgartigimod alfa-fcab injection)
• Mestinon (pyridostigmine)
• Trexall (methotrexate)
• Prograf (tacrolimus)